BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Lori Ellis

  Lori Ellis is the Head of Insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.
• 

  Deals

  5 Major ADC Deals This Year Highlight Investment Uptick

  In 2023, the ADC market exceeded $10 billion, and this momentum is persisting into 2024, as evidenced by several strategic deals and a robust pipeline of candidate drugs.

  July 2, 2024

   · 

  3 min read

   · 

  Roxanne Nelson
• 

  Policy

  Two Senior Cassava Employees Subjects in Federal Probes After Former Advisor Indicted for Fraud

  The Department of Justice and Securities and Exchange Commission are investigating two senior employees of Cassava Sciences in connection with allegations of data manipulation for its Alzheimer’s disease candidate simufilam.

  July 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  FDA Approves Eli Lilly’s Donanemab to Treat Alzheimer’s Disease

  Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.

  July 2, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Policy

  FTC Investigates Teva Over Refusal to Remove Improperly Listed Patents from Orange Book

  The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals after the company allegedly ignored directives to withdraw or amend contentious patent listings on the FDA’s Orange Book.

  July 2, 2024

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Vaccines

  Moderna to Produce Bird Flu Vaccine Under $176M BARDA Project Award
  
  

  Moderna on Tuesday announced it has been awarded $176 million by a consortium funded by the Biomedical Advanced Research and Development Authority to develop an mRNA-based vaccine to counter H5N1 avian influenza.
  
  

  July 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Deals

  Lilly Inks Radiopharma Deal With Radionetics, Secures Right to Buy Biotech

  Eli Lilly is expanding its radiopharmaceutical portfolio with a $140 million upfront payment to Radionetics Oncology and the exclusive future right to acquire the biotech for $1 billion.

  July 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  DEI

  Understanding That We Don’t Understand at a Molecular Level

  This week on Denatured, Head of Insights Lori Ellis and guests discuss the implications of not addressing the DE&I data gaps for the future.

  July 2, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Deals

  Samsung Bio Nabs $1B Manufacturing Contract With Undisclosed US Pharma

  Samsung Biologics announced Tuesday it has signed its largest contract ever—a $1.06 billion manufacturing deal with an unnamed pharmaceutical company headquartered in the U.S.

  July 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Cartesian Gets Phase II Win in Myasthenia Gravis, Looks to Raise $130M Through Financing

  Cartesian Therapeutics’ mRNA CAR-T therapy met its primary endpoint in a mid-stage trial for the chronic autoimmune disorder and expects to raise $130 million via private placement equity financing.

  July 2, 2024

   · 

  2 min read

   · 

  Kate Goodwin